Survival at 2 years at 2 years [clinicaltrials_resource:a954d6a07f0dea9293cfd9b49ca18a93]
Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.
After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.
At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.
Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Survival at 2 years at 2 years [clinicaltrials_resource:a954d6a07f0dea9293cfd9b49ca18a93]
Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.
After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.
At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.
Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.
Bio2RDF identifier
a954d6a07f0dea9293cfd9b49ca18a93
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a954d6a07f0dea9293cfd9b49ca18a93
measure [clinicaltrials_vocabulary:measure]
Survival at 2 years
time frame [clinicaltrials_vocabulary:time-frame]
at 2 years
description
Patients receive topotecan IV ...... en every 6 months for 3 years.
identifier
clinicaltrials_resource:a954d6a07f0dea9293cfd9b49ca18a93
title
Survival at 2 years at 2 years
@en
type
label
Survival at 2 years at 2 years [clinicaltrials_resource:a954d6a07f0dea9293cfd9b49ca18a93]
@en